Aller au contenu principal
Retour à l'annuaire
DL
RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

M. Docteur Dan LEVY

📍 Strasbourg (67)Libéral💶 Secteur 2RPPS 10101800927
📊 Reconnaissance scientifique : 230/100📝 1549 articles publiés📚 HAL (8)📕 1 livre

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

230

h articles cités ≥ h fois chacun. Un h de 230 = 230 publications avec 230+ citations.

Citations

249 735

Publications

1549

i10-index

931

Thématiques principales

  • Genetic Associations and Epidemiology ×228
  • Cardiovascular Function and Risk Factors ×212
  • Blood Pressure and Hypertension Studies ×154
  • Epigenetics and DNA Methylation ×123
  • Cardiovascular Disease and Adiposity ×98
Voir sur OpenAlex ↗🆔 ORCID 0000-0003-1843-8724

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

Source : Google Books — filtre catégories médicales/santé/sciences.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

🟡 Secteur 2 — Honoraires libresSource CNAM (Annuaire santé Ameli)
💳 Carte VitaleLibéral intégral
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force

    Clinical immunology (Orlando, Fla.) · 2024

    📚 15 citations🎯 RCR 3.46Top 13% NIH🔓 Open Access
  • 2
    A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry

    Rheumatology (Oxford, England) · 2024

    📚 13 citations🎯 RCR 4.63Top 9% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Objective To assess changes in juvenile idiopathic arthritis (JIA) treatments and outcomes in Canada, comparing 2005–2010 and 2017–2021 inception cohorts. Methods Patients enrolled within three months of diagnosis in the Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) and the Canadian Alliance of Pediatric Rheumatology Investigators Registry (CAPRI) cohorts were included. Cumulative incidences of drug starts and outcome attainment within 70 weeks of diagnosis were compared with Kaplan–Meier survival analysis and multivariable Cox regression. Results The 2005–2010 and 2017–2021 cohorts included 1128 and 721 patients, respectively. JIA category distribution and baseline clinical juvenile idiopathic arthritis disease activity (cJADAS10) scores at enrolment were comparable. By 70 weeks, 6% of patients (95% CI 5, 7) in the 2005–2010 and 26% (23, 30) in the 2017–2021 cohort had started a biologic DMARD (bDMARD), and 43% (40, 47) and 60% (56, 64) had started a conventional DMARD (cDMARD), respectively. Outcome attainment was 64% (61, 67) and 83% (80, 86) for inactive disease (Wallace criteria), 69% (66, 72) and 84% (81, 87) for minimally active disease (cJADAS10 criteria), 57% (54, 61) and 63% (59, 68) for pain control (<1/10), and 52% (47, 56) and 54% (48, 60) for good health-related quality of life (≥9/10). Conclusion Although baseline disease characteristics were comparable in the 2005–2010 and 2017–2021 cohorts, cDMARD and bDMARD use increased with a concurrent increase in minimally active and inactive disease. Improvements in parent and patient-reported outcomes were smaller than improvements in disease activity.

  • 3
    25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges

    Arthritis care & research · 2025

    📚 10 citations🎯 RCR 4.34🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    There are over 100 rheumatic diseases and approximately 300,000 children with a pediatric rheumatic disease (PRD) in the United States. The most common PRDs are juvenile idiopathic arthritis (JIA), childhood‐onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM). Effective and safe medications are essential because there are generally no cures for these conditions. Etanercept was the first biologic therapy for the treatment of JIA, approved in 1999. Since then, other biologic disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) blocking relevant immunologic pathways have been approved for the treatment of JIA, resulting in a marked improvement of disease prognosis. Conversely, there is only one bDMARD that has been approved for cSLE, but none are approved for the treatment of JDM. Lack of approved therapeutic options, with established dosing regimens and known efficacy and safety, remains a central challenge in the treatment of all PRDs, including autoinflammatory diseases, and for complications of PRDs. This review provides an overview of bDMARD and tsDMARD treatments studied for the treatment of various subtypes of JIA, summarizes information from bDMARD studies in other PRDs, with a focus on pivotal trials that led to regulatory approvals, and highlights improved outcomes in patients with JIA with the reception of these newer medications. Further, we outline barriers and challenges in the treatment of other PRDs. Last, we summarize the current regulatory landscape for bDMARD studies and medication approvals for patients with PRDs.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal16

▼

Lupus14

▼

Pédiatrie6

▼

Arthrite juvénile3

▼

Revue générale3

▼

Anti-TNF2

▼

Case report / série2

▼

Essai clinique2

▼

Santé mentale / fatigue2

▼

Biothérapies non-anti-TNF1

▼

csDMARDs1

▼

Génétique1

▼

Goutte1

▼

Qualité de vie / PROMs1

▼

Recommandations1

▼

Datasets & protocoles partagés

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.